Similarly, in 105 patients with metastatic BC, 39 patients (37%) with low CEA levels had significantly shorter median survival times after recurrence (18 versus 28 months) than patients with high CEA levels [69]. This evidence concerns the gene CEACAM5 and breast cancer.